What is the 13F Pro Quality Score for IMCR?

13F Pro ranks Immunocore Holdings plc (IMCR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMCR's current score at https://13fpro.ai/company/IMCR (free sign-up required for the full ranking).

Which hedge funds own the most IMCR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IMCR include WELLINGTON MANAGEMENT GROUP LLP, RTW INVESTMENTS,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/IMCR as soon as new 13F filings post.

Where does 13F Pro source IMCR data?

All Immunocore Holdings plc fundamentals and ownership data come directly from SEC EDGAR. Immunocore Holdings plc files with the SEC under CIK 1671927. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMCR in?

Immunocore Holdings plc (IMCR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMCR research updated on 13F Pro?

IMCR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Immunocore Holdings plc(IMCR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1671927 IMCR stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

36.6/100

Rank #2,263 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IMCR Scores 37/100

exact factor attribution · 2026-09-11

IMCR's composite is driven by revenue growth, held back by free cash flow and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.1 pts

85th pct

Earnings growth

-0.5 pts

41th pct

Institutional flow

-0.9 pts

31th pct

Shareholder dilution

-1.7 pts

16th pct

Capital efficiency

-2.1 pts

29th pct

Scale

-2.4 pts

34th pct

Profitability

-3.2 pts

29th pct

Earnings quality

-4.7 pts

3th pct

Free cash flow

-4.9 pts

17th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

IMCR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Immunocore Holdings plc (IMCR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMCR at 36.6/100 on a 32-signal composite quality model, placing it at rank #2,263 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Immunocore Holdings plc reports quarterly revenue of $115.9M, net income of $-808.0K, free cash flow of $15.1M. Top institutional holders of IMCR by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, RTW INVESTMENTS, FMR, based on the most recent SEC filings. IMCR trades on the Nasdaq exchange and files with the SEC under CIK 1671927. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunocore Holdings plc directly from SEC EDGAR. Immunocore Holdings plc's 13F Pro composite quality score has ranged between 35 and 45 since 2026, currently 36.6 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about Immunocore Holdings plc

Quirks, history, and lore behind IMCR — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · UK-headquartered · listed on Nasdaq · operating in oncology and infectious disease.
2
The Numbers
A small-cap biotech with revenues in the tens of millions annually, driven almost entirely by a single approved therapy — the pipeline is the whole bet.
3
The History
Founded in the early 2000s out of research from the University of Oxford, it spent nearly two decades developing a platform technology before landing its first approval.
4
The Secret
Its core platform engineers T-cell receptors to recognize targets inside cancer cells — targets that antibodies can't reach — making it a fundamentally different class of drug than most oncology therapies.
5
The Lore
Its first approved product, tebentafusp, targets a protein called gp100 and is the first treatment ever shown to improve survival in uveal melanoma, a rare and previously untreatable eye cancer.
6
The Giveaway
The company's name literally fuses "immune" and "T-cell receptor core" — its entire identity is built around its proprietary ImmTAC platform, which redirects T cells to kill tumors.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$115.9M

Net Income

Q2 2026

$-808.0K

Free Cash Flow

Q2 2026

$15.1M

ROIC

Q2 2026

-2.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+29.0% YoY

$400.0MFY 2025

FY22 $174.4MFY23 $249.4MFY24 $310.2MFY25 $400.0M

Net Income

+30.5% YoY

$-35.5MFY 2025

FY22 $-52.5MFY23 $-55.3MFY24 $-51.1MFY25 $-35.5M

Operating Income

+35.6% YoY

$-45.4MFY 2025

FY22 $-51.7MFY23 $-59.6MFY24 $-70.5MFY25 $-45.4M

EPS (Diluted)

+30.4% YoY

$-0.71FY 2025

FY22 $-1.15FY23 $-1.13FY24 $-1.02FY25 $-0.71

Total Assets

+5.7% YoY

$1.07BFY 2025

FY22 $526.8MFY23 $597.0MFY24 $1.01BFY25 $1.07B

Op. Cash Flow

-141.1% YoY

$-10.7MFY 2025

FY22 $-49.2MFY23 $2.9MFY24 $26.1MFY25 $-10.7M

Free Cash Flow

-172.1% YoY

$-15.1MFY 2025

FY22 $-51.4MFY23 $-2.5MFY24 $20.9MFY25 $-15.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$400.0M +29.0%	$310.2M +24.4%	$249.4M +43.1%	$174.4M +377.9%	$36.5M +21.2%	$30.1M
Net Income	$-35.5M +30.5%	$-51.1M +7.6%	$-55.3M -5.2%	$-52.5M +70.8%	$-180.0M	—
Operating Income	$-45.4M +35.6%	$-70.5M -18.1%	$-59.6M -15.4%	$-51.7M +70.4%	$-174.6M	—
EPS (Diluted)	$-0.71 +30.4%	$-1.02 +9.7%	$-1.13 +1.7%	$-1.15 +72.9%	$-4.24	—
Total Assets	$1.07B +5.7%	$1.01B +69.1%	$597.0M +13.3%	$526.8M +74.6%	$301.8M +53.0%	$197.2M
Operating Cash Flow	$-10.7M -141.1%	$26.1M +786.4%	$2.9M +106.0%	$-49.2M +65.6%	$-143.1M	—
Free Cash Flow	$-15.1M -172.1%	$20.9M +940.6%	$-2.5M +95.2%	$-51.4M +64.4%	$-144.5M	—

Get alerted when IMCR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Immunocore Holdings plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMCR

WELLINGTON MANAGEMENT GROUP LLP
$181.7M5,721,945 sh
RTW INVESTMENTS, LP
$154.6M4,869,798 sh
FMR LLC
$136.8M4,307,246 sh
PRIMECAP MANAGEMENT CO/CA/
$115.5M3,638,241 sh
Bellevue Group AG
$88.5M2,788,245 sh
TANG CAPITAL MANAGEMENT LLC
$84.1M2,649,368 sh
LINDEN ADVISORS LP
$71.9M78,336,000 sh
Context Capital Management, LLC
$63.7M69,292,000 sh
Vestal Point Capital, LP
$57.1M1,800,000 sh
TWO SIGMA INVESTMENTS, LP
$52.4M1,648,983 sh

Fund	Value	Shares
WELLINGTON MANAGEMENT GROUP LLP	$181.7M	5,721,945
RTW INVESTMENTS, LP	$154.6M	4,869,798
FMR LLC	$136.8M	4,307,246
PRIMECAP MANAGEMENT CO/CA/	$115.5M	3,638,241
Bellevue Group AG	$88.5M	2,788,245
TANG CAPITAL MANAGEMENT LLC	$84.1M	2,649,368
LINDEN ADVISORS LP	$71.9M	78,336,000
Context Capital Management, LLC	$63.7M	69,292,000
Vestal Point Capital, LP	$57.1M	1,800,000
TWO SIGMA INVESTMENTS, LP	$52.4M	1,648,983

Companies Similar to IMCR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SNDX

Syndax Pharmaceuticals Inc

AI score

Very similar · 14 shared holders

Kynam Capital Management, LP DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Trails Edge Capital Partners, LP

MNKD

MANNKIND CORP

AI score

Similar quality profile · 10 shared holders

Frazier Life Sciences Management, L.P.BRAIDWELL LP Deep Track Capital, LP

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Similar quality profile · 15 shared holders

TANG CAPITAL MANAGEMENT LLC BVF INC/IL Trails Edge Capital Partners, LP

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Similar quality profile · 16 shared holders

Bellevue Group AG Kynam Capital Management, LP Caligan Partners LP

PTCT

PTC THERAPEUTICS, INC.

AI score

Similar quality profile · 13 shared holders

RTW INVESTMENTS, LP TANG CAPITAL MANAGEMENT LLC ARMISTICE CAPITAL, LLC

TARS

Tarsus Pharmaceuticals, Inc.

AI score

Similar quality profile · 13 shared holders

RTW INVESTMENTS, LP TANG CAPITAL MANAGEMENT LLC Vestal Point Capital, LP

KYMR

Kymera Therapeutics, Inc.

AI score

Similar quality profile · 18 shared holders

BVF INC/IL RTW INVESTMENTS, LP BRAIDWELL LP

ARDX

ARDELYX, INC.

AI score

Similar quality profile · 12 shared holders

J. Goldman & Co LP DIADEMA PARTNERS LP Hennion & Walsh Asset Management, Inc.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMCR on your watchlist

Track score changes the day Immunocore Holdings plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMCR a good stock to buy?

13F Pro's AI-powered analysis of Immunocore Holdings plc (IMCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMCR are available on the IMCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IMCR is classified as a small company.

Which hedge funds own IMCR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immunocore Holdings plc's investment landscape.